The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
Abstract
Background— The cytochrome P450 (CYP) 2C19 isoenzyme plays an important role in clopidogrel metabolization. A recently explored CYP2C19 * 17 allelic variant has been linked to increased transcriptional activity, resulting in extensive metabolization of CYP2C19 substrates, which may lead to an enhanced platelet response to clopidogrel treatment. The aim of this study was to assess the impact of CYP2C19 * 17 on ADP-induced platelet aggregation, the risk of bleeding, and stent thrombosis in clopidogrel-treated patients undergoing percutaneous coronary intervention. Methods and Results— The study population included 1524 patients undergoing percutaneous coronary intervention after pretreatment with 600 mg clopidogrel. Genotypes were determined with a TaqMan assay. ADP-induced platelet aggregation was assessed on a Multiplate analyzer. The primary clinical safety end point was the 30-day incidence of bleeding defined according to Thrombolysis in Myocardial Infarction criteria, and the primary clinical efficacy end point was the 30-day incidence of stent thrombosis. For both heterozygous (*wt/*17; n=546) and homozygous (*17/*17; n=76) allele carriers, significantly lower ADP-induced platelet aggregation values were found compared with wild-type homozygotes (*wt/*wt; n=902; P =0.039 and P =0.008, respectively). CYP2C19 * 17 allele carriage was significantly associated with an increased risk of bleeding; the highest risk was observed for CYP2C19 * 17 homozygous patients ( P =0.01, χ 2 test for trend). Multivariate analysis confirmed the independent association of CYP2C19 * 17 allele carriage with platelet aggregation values ( P <0.001) and the occurrence of bleeding ( P =0.006). No significant influence of CYP2C19 * 17 on the occurrence of stent thrombosis was found ( P =0.79). Conclusions— CYP2C19 * 17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
Collet, J.-P., Hulot, J.-S., Pena, A., Villard, E., Esteve, J.-B., Silvain, J., Payot, L., Brugier, D., Cayla, G., Beygui, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61845-0 · Cited by 967
Hulot, J.-S. (2006) · Blood · doi:10.1182/blood-2006-04-013052 · Cited by 931
Moscucci, M. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00485-8 · Cited by 918
Manoukian, S. V., Feit, F., Mehran, R., Voeltz, M. D., Ebrahimi, R., Hamon, M., Dangas, G. D., Lincoff, A. M., White, H. D., Moses, J. W., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.027 · Cited by 798
Identification and Biological Activity of the Active Metabolite of Clopidogrel
Savi, P., Pereillo, J. M., Uzabiaga, M. F., Combalbert, J., Picard, C., Maffrand, J. P., Pascal, M., & Herbert, J. M. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614133 · Cited by 754
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis
Buonamici, P., Marcucci, R., Migliorini, A., Gensini, G. F., Santini, A., Paniccia, R., Moschi, G., Gori, A. M., Abbate, R., & Antoniucci, D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.094 · Cited by 656
Price, M. J., Endemann, S., Gollapudi, R. R., Valencia, R., Stinis, C. T., Levisay, J. P., Ernst, A., Sawhney, N. S., Schatz, R. A., & Teirstein, P. S. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn046 · Cited by 651
Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., Schömig, A., Kastrati, A., & von Beckerath, N. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.030 · Cited by 651
Self-citationHochholzer, W., Trenk, D., Bestehorn, H.-P., Fischer, B., Valina, C. M., Ferenc, M., Gick, M., Caputo, A., Büttner, H. J., & Neumann, F.-J. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.065 · Cited by 589
Kinnaird, T. D., Stabile, E., Mintz, G. S., Lee, C. W., Canos, D. A., Gevorkian, N., Pinnow, E. E., Kent, K. M., Pichard, A. D., Satler, L. F., et al. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00972-x · Cited by 542
Trenk, D., Hochholzer, W., Fromm, M. F., Chialda, L.-E., Pahl, A., Valina, C. M., Stratz, C., Schmiebusch, P., Bestehorn, H.-P., Büttner, H. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.056 · Cited by 540
Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis
Gurbel, P. A., Bliden, K. P., Samara, W., Yoho, J. A., Hayes, K., Fissha, M. Z., & Tantry, U. S. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.056 · Cited by 536
Platelet Function Monitoring in Patients With Coronary Artery Disease
Gurbel, P. A., Becker, R. C., Mann, K. G., Steinhubl, S. R., & Michelson, A. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.051 · Cited by 478
Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions
Ndrepepa, G., Berger, P. B., Mehilli, J., Seyfarth, M., Neumann, F.-J., Schömig, A., & Kastrati, A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.040 · Cited by 471
Self-citationSibbing, D., Stegherr, J., Latz, W., Koch, W., Mehilli, J., Dorrler, K., Morath, T., Schomig, A., Kastrati, A., & von Beckerath, N. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehp041 · Cited by 418
Self-citationMehran, R., Pocock, S. J., Stone, G. W., Clayton, T. C., Dangas, G. D., Feit, F., Manoukian, S. V., Nikolsky, E., Lansky, A. J., Kirtane, A., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp110 · Cited by 365
Pharmacokinetics of clopidogrel after administration of a high loading dose
Kastrati, A., Harlfinger, S., Gorchakova, O., Lazar, A., von Beckerath, N., Schömig, A., Schömig, E., & Taubert, D. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-02-0105 · Cited by 240
Self-citationGeisler, T., Schaeffeler, E., Dippon, J., Winter, S., Buse, V., Bischofs, C., Zuern, C., Moerike, K., Gawaz, M., & Schwab, M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.9.1251 · Cited by 213
Weiss, J., ten Hoevel, M. M., Burhenne, J., Walter‐Sack, I., Hoffmann, M. M., Rengelshausen, J., Haefeli, W. E., & Mikus, G. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008327537 · Cited by 208
Wang, G., Lei, H.-P., Li, Z., Tan, Z.-R., Guo, D., Fan, L., Chen, Y., Hu, D.-L., Wang, D., & Zhou, H.-H. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0574-7 · Cited by 173
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
Rosenborg, S., Mwinyi, J., Andersson, M., Baldwin, R. M., Pedersen, R. S., Sim, S. C., Bertilsson, L., Ingelman‐Sundberg, M., & Eliasson, E. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0529-z · Cited by 68
Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites
Heestermans, A. A. C. M., van Werkum, J. W., Schömig, E., ten Berg, J. M., & Taubert, D. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01891.x · Cited by 29
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“, 2008) while another study reported increased risk of bleeding events (Sibbing et al., 2010).”
BackgroundHicks, J., Bishop, Jr., Sangkuhl, K., Müller, D., Ji, Y., Leckband, S., Leeder, J., Graham, R., Chiulli, D., LLerena, A., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.147 · Cited by 998
Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J.-S., Mega, J. L., Roden, D. M., Klein, T. E., Sabatine, M. S., Johnson, J. A., & Shuldiner, A. R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.105 · Cited by 962
Wallentin, L., James, S., Storey, R. F., Armstrong, M., Barratt, B. J., Horrow, J., Husted, S., Katus, H., Steg, P. G., Shah, S. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61274-3 · Cited by 799
Sibbing, D., Aradi, D., Alexopoulos, D., ten Berg, J., Bhatt, D. L., Bonello, L., Collet, J.-P., Cuisset, T., Franchi, F., Gross, L., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.03.034 · Cited by 537
Self-citation
Metadata
- Authors
- Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., Morath, T., Schömig, A., von Beckerath, N., & Kastrati, A.
- Venue
- Circulation
- Published
- 2010-02-02
- Volume
- 121
- Issue
- 4
- Pages
- 512-518
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2017294431
- Cited by
- 585
- References
- 27
- FWCI
- 56.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.